BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 21555967)

  • 1. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.
    Lim JW; Lee HK; Shin MC
    Ophthalmologica; 2012; 227(2):100-6. PubMed ID: 21997197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
    Soheilian M; Garfami KH; Ramezani A; Yaseri M; Peyman GA
    Retina; 2012 Feb; 32(2):314-21. PubMed ID: 22234244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial macular thickness and response to treatment in diabetic macular edema.
    Soheilian M; Ramezani A; Yaseri M; Mirdehghan SA; Obudi A; Bijanzadeh B
    Retina; 2011 Sep; 31(8):1564-73. PubMed ID: 21451442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
    El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
    Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion.
    Ramezani A; Esfandiari H; Entezari M; Moradian S; Soheilian M; Dehsarvi B; Yaseri M
    Acta Ophthalmol; 2014 Nov; 92(7):e530-9. PubMed ID: 24373344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
    Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
    Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal Bevacizumab with or without Triamcinolone for Wet Age-related Macular Degeneration: Twelve-month Results of a Prospective, Randomized Investigation.
    Motarjemizadeh Q; Aidenloo NS; Abbaszadeh M; Sadrinia V
    Middle East Afr J Ophthalmol; 2018; 25(1):1-7. PubMed ID: 29899643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for neovascular age-related macular degeneration in China.
    Li X; Hu Y; Sun X; Zhang J; Zhang M;
    Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
    Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
    Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.